Polyplus Launches Innovative Plasmid for AAV Vector Production, Strengthening Its Position in Biologic and Cell & Gene Therapy Solutions
Singapore, March 27 -- Polyplus (part of Sartorius, a distinguished upstream solutions provider for biologic and cell and gene therapy production and a part of the Sartorius group, has announced the introduction of pPLUS(R) AAV-RC2, a groundbreaking RepCap plasmid tailored for the production of adeno-associated virus vector 2 (AAV2). This launch is a significant addition to Polyplus's portfolio, aligning with the company's strategic direction to become a leading provider of critical raw materials for AAV production.
The pPLUS AAV-RC2 plasmid, now available off-the-shelf, is designed to streamline the manufacturing process for AAV vectors, offering a ready-to-use solution that enhances both efficiency and reliability in vector production....
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.